(
84
Results
)
Filter
Only match titles
What are you looking for?
-
Category
-
Type
-
Year
-
Keywords
-
Author
Apply filters
Knowledge Hub
Collapse
-
EAACI position paper: Comparing insect hypersensitivity induced by bite, sting, inhalation or ingestion in human beings and animals
-
EAACI position paper: Influence of dietary fatty acids on asthma, food allergy, and atopic dermatitis
-
EAACI/ENDA Position Paper: Diagnosis and management of hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) in children and adolescents
-
Eosinophils – from cradle to grave: An EAACI task force paper on new molecular insights and clinical functions of eosinophils and the clinical effects of targeted eosinophil depletion
-
The roadmap for allergology in Europe: The subspecialty of allergology as “stop-over” on the way to a full specialty. An EAACI position statement
-
A practical toolbox for the effective transition of adolescents and young adults with asthma and allergies: An EAACI position paper
-
ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – an EAACI-ARIA Position Paper
-
Allergies and COVID-19 vaccines: An ENDA/ EAACI Position paper
-
AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus-A joint EAACI-EANO position paper
-
AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper
-
AllergoOncology: Microbiota in allergy and cancer – A European Academy for Allergy and Clinical Immunology position paper
-
AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer – a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI)
-
Alpine Altitude Climate Treatment for severe and uncontrolled asthma: an EAACI Position Paper
-
An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions
-
Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper
-
Biologicals in atopic disease in pregnancy: An EAACI position paper
-
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ ARIA Position Paper
-
Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper
-
Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD) – a EAACI position paper
-
Diagnosis and management of Non-IgE gastrointestinal allergies in breastfed infants – An EAACI Position Paper
-
Diagnosis and management of allergy and respiratory disorders in sport: An EAACI task force position paper
-
Diagnosis and management of drug-induced anaphylaxis in children: An EAACI position paper
-
Diagnosis and management of food allergy-associated gastroesophageal reflux disease in young children – EAACI position paper
-
Diagnosis and management of food allergy-induced constipation in young children—An EAACI position paper
-
Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19: An EAACI position paper
-
Digitally-enabled, person-centred care (PCC) in allergen immunotherapy: An ARIA-EAACI Position Paper
-
EAACI Position paper on the standardization of nasal allergen challenges
-
EAACI position paper on diet diversity in pregnancy, infancy and childhood: Novel concepts and implications for studies in allergy and asthma
-
EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity
-
EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities
-
EAACI/ENDA position paper on drug provocation testing
-
European Academy of Allergy and Clinical Immunology position paper on endoscopic scoring of nasal polyposis
-
Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper
-
Food processing and occupational respiratory allergy- An EAACI position paper
-
Genetic variants associated with T cell-mediated cutaneous adverse drug reactions: A PRISMA-compliant systematic review – An EAACI position paper
-
Granulocytes and mast cells in AllergoOncology—Bridging allergy to cancer: An EAACI position paper
-
Hypersensitivity reactions to biological agents: An EAACI position paper
-
Hypersensitivity reactions to chemotherapy: an EAACI position paper
-
Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper
-
Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the task force on immunopharmacology (TIPCO)
-
In-vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan – An EAACI position paper
-
Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper
-
Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology
-
Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper
-
Omics technologies in allergy and asthma research: An EAACI position paper
-
One Health: EAACI Position Paper on coronaviruses at the human-animal interface, with a specific focus on comparative and zoonotic aspects of SARS-CoV-2
-
Pathogenesis, immunology, and immune-targeted management of the multisystem inflammatory syndrome in children (MIS-C) or pediatric inflammatory multisystem syndrome (PIMS): EAACI Position Paper
-
Placebo effects in allergen immunotherapy – An EAACI Task Force Position Paper
-
Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper
-
Respiratory diseases and allergy in farmers working with livestock: a EAACI position paper
-
Role of dietary fiber in promoting immune health – An EAACI position paper
-
Skin microdialysis: methods, applications and future opportunities – an EAACI position paper
-
Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper
-
State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI)
-
Telemedicine with special focus on allergic diseases and asthma—Status 2022: An EAACI position paper
-
The Bronchodilator and Anti-Inflammatory Effect of Long-Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper
-
The roadmap for the Allergology specialty and allergy care in Europe and adjacent countries. An EAACI position paper
-
The role of mobile health technologies in allergy care: An EAACI position paper
-
Toward clinically applicable biomarkers for asthma: An EAACI position paper
-
Towards a more precise diagnosis of hypersensitivity to beta-lactams – an EAACI position paper
Show more Position Papers (58)Show Less-
-
EAACI/ENDA Position Paper: Diagnosis and management of hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) in children and adolescents
-
ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – an EAACI-ARIA position paper
-
Allergies and COVID-19 vaccines: An ENDA/ EAACI Position paper
-
AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus-A joint EAACI-EANO position paper
-
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic – An EAACI/ARIA position paper
-
Digitally-enabled, person-centred care (PCC) in allergen immunotherapy: An ARIA-EAACI Position Paper
-
EAACI/ENDA position paper on drug provocation testing
-
Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper
Show more Consensus Documents (6)Show Less-
-
Position statement of expert panel of the Polish Allergology Society (PTA) on the management of patients with bronchial asthma and allergic diseases during the SARS-CoV-2 pandemic
-
ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines – an EAACI‐ARIA position paper
-
Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic – An EAACI Position Paper
Show more Covid-19 (1)Show Less-
Website
Collapse
-
EUROBAT Symposium 2 – Guidelines, position papers and consensus protocols for BAT
-
How to get your paper published in a high-impact journal
-
Identification of a novel non-specific lipid transfer protein from Paper Mulberry pollen
-
Polistes gallicus: an alternative treatment for European paper wasp venom allergic patients?
-
EAACI position paper about basophil activation test in immediate drug hypersensitivity
-
The Prevalence of NSAID‐exacerbated Respiratory Disease in one allergy center from China: Diagnosis adhering to EAACI Position Paper
Show more Sessions (4)Show Less-